HTB South

Conference reports

16th European AIDS Conference (EACS 2017)

Studies on dolutegravir and sleep, cardiovascular and CNS side effects, and risk of IRIS

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed

No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load

9th IAS Conference on HIV Science (IAS 2017)

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

Reduced-dose darunavir is safe and effective in switch study

Preliminary results on dolutegravir use in pregnancy are reassuring

Low dose efavirenz (EFV400) can be used during pregnancy

Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold

Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high

9th International Workshop on HIV Paediatrics, 21–22 July 2017, Paris

Chewable raltegravir tablets can be crushed and dispersed in liquid for young children

18th International Workshop on Clinical Pharmacology of Antiviral Therapy, 14-16 June 2017, Chicago

Dolutegravir pharmacokinetics in pregnancy

High rates of undocumented efavirenz-related side effects in Uganda

11th INTEREST Workshop, 16-19 May 2017, Lilongwe, Malawi

Increased risk of ART failure after low-level viraemia in a large South African cohort

Option B+ Malawi

24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence

Increased risk of IRIS with integrase inhibitors reported in two studies

Dolutegravir exposure increases when fixed dose combination tablets are crushed

Dose reduction potential of nanoparticle ARV formulations confirmed in humans

Breakthrough for treating XDR-TB and ameliorating TB-IRIS

Significant interaction between once-weekly isoniazid/rifapentine and daily dolutegravir: study stopped due to toxicity

Adverse pregnancy outcomes and risk factors in the PROMISE trial

PrEP in pregnancy does not increase poor birth outcomes

Pharmacokinetics, safety and efficacy of dolutegravir in very young children

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

Tenofovir alafenamide exposure modestly higher in children than adults

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

World Health Organisation paediatric dosing tool

Paediatric HIV: CROI 2017

16th European AIDS Conference (EACS 2017)

9th IAS Conference on HIV Science (IAS 2017)

Featured Reports from the 18th PK and 11th INTEREST Workshops

More reports from CROI 2017

First reports from CROI 2017…

International Congress of Drug Therapy in HIV infection (Glasgow 2016), 23-26 October 2016

Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients

Further reports of CNS-related side effects with dolutegravir

2nd HIV Research for Prevention Conference (HIVR4P) 2016, 17-20 October 2016, Chicago

A burgeoning PrEP pipeline: dozens of new drugs, formulations and delivery options

Second case of drug resistant HIV infection in person adherent on PrEP

TDF/FTC can be used as PrEP by breastfeeding mothers without risk to the baby

Potential for EFdA as PrEP to prevent HIV transmission in women and their infants

Antibody therapy leads to sustained post-treatment SIV control in macaques

21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa

Dolutegravir is superior to boosted atazanavir in women in the ARIA study

Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study

Once-daily raltegravir at last available: 48 week results from ONCEMRK study

Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2

Efavirenz associated with suicide risk in analysis from START study

PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence

Birth weight and preterm delivery outcomes of vertically vs non-vertically infected HIV positive pregnant women

High death rates among HIV positive women postpartum accessing ARVs

Higher rates of eye complications in HIV positive people on ART

Sub-Saharan African countries moving quickly to recommend “Treat All”

ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms

Global HIV Clinical Forum: Integrase Inhibitors, 16 July 2016, Durban

Raltegravir-based third-line ART in children and adolescents

8th International Workshop on HIV Paediatrics, 15-16 July 2016, Durban, South Africa

No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial

Post navigation